Gadi Lachman, CEO of TriNetX told us that the real-world data Allergan will have access to involves clinical data from the electronic medical records (EMR), genomics, and oncology among other things.
TriNetX says its platform provides industry members with access to patient populations, cohort analysis, and site identification services. The TriNetX platform includes real-time access to de-identified real-world data from more than 135 million patients.
“[Access to real-world data] is core to how protocols are designed and ultimately how a drug goes to market,” said Lachman. “There are also platform features that allow pharma and healthcare organizations to collaborate on study opportunities and placement.”
The TriNetX network has partnerships with household pharmaceutical and health care companies like Sanofi, Pfizer, Tufts, and Boston Children’s Hospital. Allergan is the latest to join the other well-known companies in the network.
TriNetX recently released tools that enable health research on a wider spectrum. The company currently has a cloud-platform called TNX, which provides longitudinal clinical data and analytics. More tools will be released later this year and will build on the current and new tools available on the TriNetX platform.
TriNetX has said that it is working towards addressing the importance of real-world data to generate real-world evidence, and is aiming to provide access to it through tools on its platform.
To provide this network of data assets TriNetX is partnered with over 80 healthcare organizations in over 16 countries.